EUCTR2006-001999-20-CZ
进行中（未招募）
不适用
ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (ROZEX®), IN PATIENTS WITH PAPULO-PUSTULAR ROSACEA OVER 12 WEEKS
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- Patients with papulo-pustular rosacea
- 发起方
- Galderma Research & Development SNC
- 入组人数
- 270
- 状态
- 进行中（未招募）
- 最后更新
- 14年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Male or female subjects with papulo\-pustular rosacea with at least 15 inflammatory facial lesions, at least 18 years old, meeting specific inclusion and exclusion criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
排除标准
- •1\. The subject has particular forms of rosacea (rosacea conglobata, rosacea fulminans, and secondary rosacea form, isolated erythrosis, isolated rhinophyma, or isolated pustulosis of the chin),
- •2\. The subject has other dermatological disorders such as peri\-oral dermatitis, other forms of demodicidosis, facial keratosis pilaris, actual or history of seborrheic dermatitis, which may confound the study assessments,
结局指标
主要结局
未指定
相似试验
进行中（未招募）
不适用
ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (ROZEX®), IN PATIENTS WITH PAPULO-PUSTULAR ROSACEA OVER 12 WEEKSEUCTR2006-001999-20-HUGalderma Research & Development SNC270
进行中（未招募）
不适用
ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (ROZEX®), IN PATIENTS WITH PAPULO-PUSTULAR ROSACEA OVER 12 WEEKSPatients with papulo-pustular rosaceaMedDRA version: 9.0Level: LLTClassification code 10039218EUCTR2006-001999-20-DEGalderma Research & Development SNC274
尚未招募
不适用
COMPARING SAFETY AND EFFICACY OF 3 DIFFERENT DOSES OF FENTANYL TO HEMODYNAMIC STRESS RESPONSE TO LARYNGOSCOPY AND INTUBATIOCTRI/2021/07/035113DEPARTMENT OF ANESTHESIOLOGY
进行中（未招募）
1 期
A Phase 3 Evaluation of the Safety and Efficacy of Lambda/RBV/DCV in Treatment Naïve Subjects with Chronic HCV Infection, who have Underlying Mild or Moderate Hemophilia or Patients who are Prior Relapsers to Pegylated interferon alfa/RBVChronic Hepatitis C Virus Infection (Genotype 1, 2, 3, 4)MedDRA version: 14.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2012-003463-22-FRBristol-Myers Squibb International Corporation71
尚未招募
2 期
Evaluation and comparison of the efficacy of triple therapies regimens containing esomeprazole and different doses of amoxicillin and bismuth for eradicating Helicobacter pylori infection in SariIRCT20210518051335N1Mazandaran University of Medical Sciences200